New Development Agreement Targeting Cannabinoid Therapies Signed by Neurotech
A recent press release announced a new development agreement between Neurotech and RH Pharma focused on cannabinoid therapies.
Image | adobe.stock/Pitchayaarch
In a recent press release (1), Neurotech International Limited (Neurotech), a clinical-stage biopharmaceutical company specialized in pediatric neurological disorders, disclosed that the establishment had signed a Development Agreement with RH Pharma, a company involved in the development of cannabis products that are used in pharmaceutical applications.
Through this Development Agreement, Neurotech will be able to utilize the services of the European Cannabis Company (ECC) for manufacturing cannabis products used in pharmaceuticals. RH Pharma will handle a “controlled recombination process of highly purified cannabinoids from standard cannabis strains under Good Manufacturing Practice (GMP), and relevant other pharmaceutical standards, into a broad-spectrum cannabinoid drug product reflecting Neurotech’s compositional standards, and that meets global regulatory standards,” (1). Through this partnership, both Neurotech and RH Pharma, are able to bring products to international marketplaces.
“As we accelerate our plans for registration of NTI64 in Australia via a provisional registration strategy initially, it will be important for Neurotech to scale production to meet future product demand upon regulatory approval(s). Our commitment to regulatory compliance and quality is further strengthened by collaborations with leading medical institutions and key clinicians, reinforcing our position within the industry,” Dr Anthony Filippis, CEO and Managing Director of Neurotech International said (1). “We are delighted to partner with ECC, a company renowned for its expertise in cannabis product development. This agreement not only accelerates our global growth strategy but also ensures we can deliver premium-quality products with unparalleled consistency and scalability, independent of strain-specific limitations.
“ECC is thrilled to collaborate with Neurotech on this transformative partnership,” Rebeka Levy, General Manager of European Cannabis Company, expressed (1). “Our shared vision for innovation and international expansion positions us to deliver exceptional products to meet growing global demand.”
Key points on the agreement mentioned in the press release include (1):
• Neurotech enters partnership agreement with RH Farma Dooel Skopje (RH Pharma), a subsidiary of European Cannabis Company (ECC), a European leader in the development and scale-up of cannabis-based products for pharmaceutical applications
• The development aims to generate a strain-agnostic, pharmaceutical-grade broad spectrum cannabinoid drug product suitable for paediatric patients with neurodevelopmental disorders based on RH Pharma’s proprietary CO2 extraction technology
• Aligns with Neurotech’s proprietary composition and formulation consisting of certain cannabinoids at specific concentrations that has demonstrated significant improvement in patients with progressive neuroinflammatory disorders including autism, Rett Syndrome, and PANDAS/PANS
• An Initial upfront payment of €25,000 with additional services as requested by Neurotech with an initial term of 12 months
Reference
- Neurotech Signs New Development Agreement for Cannabinoid Therapies, https://api.investi.com.au/api/announcements/nti/38c9d4a8-d66.pdf (accessed Feb 14, 2025)
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
